JAMA Oncology,
This retrospective analysis suggests that osimertinib may be more potent than rociletinib at clinical doses in patients exposed…
This retrospective analysis suggests that osimertinib may be more potent than rociletinib at clinical doses in patients exposed…
This case series of 9 EGFR mutation-positive patients with lung cancer who have progressed on the third generation EGFR…
This retrospective analysis suggests that osimertinib may be more potent than rociletinib at clinical doses in patients exposed…